Another study examining mice carrying a pathogenic missense mutant of BRCA1 (C61G), which not only inactivates the E3 ligase activity but also disrupts BRCA1 interaction with BARD1 [19], showed that this mutation, although compromised tumor suppression function of BRCA1, affects response to therapy possibly through residual activity of this mutant in DNA repair [22]. This evidence concerns the gene BRCA1 and neoplasm.